Invivyd, Inc. (IVVD)

Market Cap	91.88M
Revenue (ttm)	11.56M
Net Income (ttm)	-225.14M
Shares Out	119.62M
EPS (ttm)	-1.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,029,172
Open	0.763
Previous Close	0.767
Day's Range	0.742 - 0.805
52-Week Range	0.722 - 5.200
Beta	0.66
Analysts	Strong Buy
Price Target	7.11 (+825.66%)
Earnings Date	Nov 14, 2024

About IVVD

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in precl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 95
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Analyst Forecast

According to 5 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price forecast is $7.11, which is an increase of 825.66% from the latest price.

Price Target

$7.11

(825.66% upside)

Analyst Consensus: Strong Buy